Pages that link to "Q34396189"
Jump to navigation
Jump to search
The following pages link to Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation (Q34396189):
Displaying 50 items.
- Integrating mutation variant allele frequency into clinical practice in myeloid malignancies (Q26748915) (← links)
- Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy (Q26749870) (← links)
- Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management (Q26796240) (← links)
- Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? (Q26801573) (← links)
- Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering (Q28083303) (← links)
- Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? (Q28387115) (← links)
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes (Q28392451) (← links)
- Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens (Q30240238) (← links)
- Treatment of low-risk myelodysplastic syndromes (Q30240278) (← links)
- Established and emerging targeted therapies in the myelodysplastic syndromes (Q30245476) (← links)
- Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. (Q30353404) (← links)
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. (Q33427165) (← links)
- Myelodysplastic syndromes: Contemporary review and how we treat (Q33429195) (← links)
- Molecular Testing in Patients with Suspected Myelodysplastic Syndromes (Q33435980) (← links)
- Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies (Q33574178) (← links)
- Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation (Q33615619) (← links)
- The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia (Q33796552) (← links)
- Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome. (Q35016534) (← links)
- Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplasti (Q35146316) (← links)
- Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations (Q35890662) (← links)
- Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes (Q36054758) (← links)
- Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients (Q36264692) (← links)
- Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells (Q36274044) (← links)
- Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing (Q36635154) (← links)
- Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia (Q36789428) (← links)
- Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis (Q37005057) (← links)
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents (Q37046564) (← links)
- Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome (Q37207443) (← links)
- Mutations in histone modulators are associated with prolonged survival during azacitidine therapy (Q37225482) (← links)
- Leukemic survival factor SALL4 contributes to defective DNA damage repair (Q37389409) (← links)
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes (Q37392696) (← links)
- Hypomethylating agents after allogeneic blood stem cell transplantation (Q37531039) (← links)
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (Q37624593) (← links)
- Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome (Q37656412) (← links)
- Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants (Q37681792) (← links)
- Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome (Q37688233) (← links)
- Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts (Q37707098) (← links)
- Lessons from the atomic bomb about secondary MDS. (Q38252814) (← links)
- The molecular pathogenesis of the myelodysplastic syndromes (Q38341998) (← links)
- Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways (Q38379074) (← links)
- Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. (Q38394646) (← links)
- The clonal origins of leukemic progression of myelodysplasia (Q38406756) (← links)
- Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. (Q38442976) (← links)
- Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment (Q38451022) (← links)
- Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents (Q38540859) (← links)
- Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate? (Q38540862) (← links)
- Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. (Q38606945) (← links)
- Therapy-related myeloid neoplasms: when genetics and environment collide (Q38611096) (← links)
- Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help? (Q38716306) (← links)
- Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation (Q38726652) (← links)